Disease-modifying anti-rheumatic drugs til behandling af ankyloserende spondylitis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Ankylosing spondylitis (AS) is an inflammatory disorder affecting the axial skeleton, peripheral joints, entheses and extra-articular sites. Patients with early disease, a higher level of erythrocyte sedimentation rate and/or peripheral arthritis might benefit from sulfasalazine. Otherwise, there is no evidence that disease-modifying anti-rheumatic (DMARDs) have a therapeutic effect in AS. Clinical evidence that greater TNF-inhibitor effectiveness can be achieved by combining with a DMARD is lacking, but further studies should be performed. More research is needed to clarify the role of DMARDs in the treatment of AS.
Udgivelsesdato: 2009-Aug
Udgivelsesdato: 2009-Aug
Bidragets oversatte titel | Disease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis |
---|---|
Originalsprog | Dansk |
Tidsskrift | Ugeskrift for læger |
Vol/bind | 171 |
Udgave nummer | 33 |
Sider (fra-til) | 2268-72 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 2009 |
ID: 20318991